- Home
- SOR vs PALI Comparison
SOR vs PALI Comparison
Compare SOR & PALI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
N/A
Current Price
$2.06
Company Overview
Basic Information| Metric | SOR | PALI |
|---|---|---|
| Founded | N/A | 1996 |
| Country | United States | United States |
| Employees | N/A | 14 |
| Industry | Investment Managers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 383.4M | 359.0M |
| IPO Year | 1995 | 2019 |
Fundamental Metrics
Financial Performance| Metric | SOR | PALI |
|---|---|---|
| Price | $46.56 | $2.06 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $11.29 |
| AVG Volume (30 Days) | 10.3K | ★ 1.7M |
| Earning Date | 01-01-0001 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 97.06 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $260,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 1500.39 |
| 52 Week Low | $44.20 | $0.55 |
| 52 Week High | $50.41 | $2.86 |
Technical Indicators
Market Signals| Indicator | SOR | PALI |
|---|---|---|
| Relative Strength Index (RSI) | 47.30 | 49.23 |
| Support Level | $45.99 | $1.93 |
| Resistance Level | $46.77 | $2.17 |
| Average True Range (ATR) | 0.71 | 0.10 |
| MACD | -0.10 | -0.00 |
| Stochastic Oscillator | 30.43 | 37.50 |
Price Performance
Historical Comparison SOR
PALI
About SOR Source Capital Inc.
Source Capital Inc is a diversified, closed-end management investment company. The investment objective of the company is to seek maximum total return for Common shareholders from both capital appreciation and investment income to the extent consistent with the protection of invested capital.
About PALI Palisade Bio Inc.
Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. Its portfolio consists of a PALI-2108 for the treatment of IBD, including UC and CD, and is researching PALI-1908.